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ABSTRACT
Prospective studies have demonstrated that an imbalance between
oxidative damage and antioxidative protection can play a role in the
development and progression of atherosclerosis. Also, genotypes with the
apolipoprotein E ε4 allele have been associated with an increase risk for
this pathology. Based on this knowledge, the aim of this study was to eval-
uate indicators of the redox balance, trace elements, and apolipoprotein E
allelic profile in subjects from the Lisbon population with clinically stable
atherosclerosis, at risk for atherosclerotic events, and in healthy subjects for
comparison. The activities of superoxide dismutase in erythrocytes and
glutathione peroxidase in whole blood, plasma total thiols, and serum
ceruloplasmin were kept unchanged among the three groups. Serum α-
tocopherol was increased in atherosclerotic patients. Total malondialde-
hyde in serum and protein carbonyls in plasma, which are indicators of
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lipid and protein oxidative damage, respectively, reached their highest values
in risk subjects. The concentrations of potassium and calcium, in plasma
and in blood cells, were slightly elevated in patients and might reflect an
electrolytic imbalance. Regarding the apolipoprotein E polymorphism,
atherosclerotic patients had an increased incidence of the high-risk geno-
types for atherogenesis (ε3/ε4 and ε4/ε4). A multivariate model applied to
the general population using most of the parameters clearly separated the
three groups at study (i.e., the healthy group from the steady-state group
of risk disease and from the atherosclerotic one). As shown by us, the use-
fulness of biochemical and complementary genetic markers is warranted
for a better knowledge on atherosclerosis molecular basis.
Index Entries: Atherosclerosis; antioxidant defenses; oxidative dam-
age; trace elements; apolipoprotein E.
INTRODUCTION
Although mortality from coronary heart disease has declined recently,
atherosclerosis and related vascular diseases are still the major causes of
death in Western countries (1,2), including Portugal. Atherosclerosis is a
chronic disease of large and medium-sized arteries, with hardening and loss
of elasticity of the arterial walls and narrowing of the arterial lumen (1).
High blood pressure, diabetes, smoking, and a diet rich in lipids and cho-
lesterol clearly increase the likelihood of premature atherosclerosis,
although other factors, such as age and the individual genetic makeup (as
apolipoprotein E), might play an additional role (3–5). Apolipoprotein (apo)
E gene expression affects the cholesterol metabolism (6,7) (more than any
other gene identified so far), and the ε4 allele, in particular, has been associ-
ated with coronary artery and heart diseases, stroke, cognitive dysfunction,
and Alzheimer’s disease, as it promotes enhanced levels of both total cho-
lesterol and low-density lipoprotein (LDL) cholesterol in plasma (8,9).
The oxidation theory of atherosclerosis proposes that the formation of
oxidized LDL in the subendothelial space of the artery wall represents a
causative event for atherogenesis (5,10,11), through their enhanced uptake
by unregulated macrophage scavenger receptor, and their immunogenic-
ity, and capacity for inducing chemotactic, cytotoxic, and growth factors
(12). Antioxidants are thought to be potential antiatherogenic compounds
(13). LDL is the primary carrier of cholesterol in the circulation, and its
components, unsaturated fatty acids and proteins, are sensitive to oxida-
tion. Endothelial cells, smooth muscle cells, and macrophages can release
free radicals and other oxidant species leading to LDL modification. How-
ever, differences exist in the susceptibility of these lipoproteins to oxida-
tive stress because small, dense LDL particles are more susceptible to
oxidation than larger LDL subfractions and because LDL particles
enriched with monounsaturated fatty acids are less prone to oxidation
than those containing high levels of polyunsaturated fatty acids (14).
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Although a number of randomized trials have failed to show any ben-
efit from antioxidant treatment, there remains a preponderance of basic and
clinical evidence in supporting the role of oxidative processes in atheroge-
nesis (15–17). Fundamental research on redox status and oxidative damage
mechanisms in atherosclerosis and associated pathologies (such as cardio-
vascular disease and stroke) becomes an important goal and might help
one to select more appropriate study designs in terms of preventive meas-
ures in populations. The present study was developed under the scope of a
project aiming to evaluate possible variations on redox balance markers,
trace elements, and apo E polymorphism in subjects from the Lisbon pop-
ulation, from the healthy to clinically stable atherosclerotic condition,
including the hazardous situation of hyperlipidemia and/or hypertension.
This article reports data on blood activities of superoxide dismutase (SOD)
and glutathione peroxidase (GPx), plasma concentration of total thiols, and
α-tocopherol levels in serum. The protein ceruloplasmin (Cp), which is con-
sidered to have an antioxidant action and to be an inflammatory marker,
was quantified in serum. Serum levels of total malondialdehyde (MDA)
and plasma contents of protein carbonyls were evaluated as markers of
oxidative modifications in lipids and proteins, respectively. The levels of
essential elements—K (potassium), Ca (calcium), Fe (iron), Cu (copper), Zn
(zinc), and Se (selenium)—playing a role in electrolytic mechanisms and
oxidant/antioxidant pathways were determined in blood. The allelic pro-
file of apo E was assessed for each subject and correlated with its clinical
condition.
MATERIALS AND METHODS
Study Design
A total of 72 nonsmoker subjects from Lisbon, ranging in age from
40 to 78 yr, were included in the study and divided into 3 groups (Table
1). The pathological group was composed of ambulatory patients with a
history of atherosclerotic disease: previous myocardial infarction,
angina, and lower limb chronic arterial insufficiency, under therapy.
Patients with acute or decompensated disorders (heart failure, respira-
tory disorders, and other metabolic abnormalities) were excluded from
the study. The subjects from the risk group were hypertensive and/or
hyperlipidemic. The reference group was composed by healthy subjects
whose lipid and blood pressure values were within normal ranges. All
subjects gave informed consent and filled out a clinical report stating
information relevant to the study, namely baseline characteristics and
lifestyles (e.g., smoking habits). Subjects under dietary supplements or
drugs with a known antioxidant capacity were excluded. The study was
approved by the Human Ethics Committee of the National Health Insti-
tute Dr. Ricardo Jorge and conformed to standard ethical guidelines for
human research.
Redox Balance in Atherosclerosis 59
Biological Trace Element Research Vol. 112, 2006
Blood Collection
The blood was collected by venipuncture after an overnight fast and
aliquots were drawn into Z-Gel, lithium–heparin, and EDTA S-Monovette®
tubes. Serum and plasma were removed after centrifugation at 1500g for
10 min at 4°C. Lipid parameters and the enzyme activities were evaluated
within 24 h. Samples for DNA extraction were stored at –70°C. Aliquots for
elemental analysis were frozen at –20°C and those for total thiols, proteins,
protein carbonyls, and Cp quantification were frozen at –80°C. For the
determination of α-tocopherol levels and lipid peroxidation index,
aliquots were kept under liquid nitrogen. Serum, plasma, and blood sam-
ples from the three groups were analyzed in the same run.
Anthropometric Measurements
Body height and weight of the participants (without shoes and heavy
clothing) were registered and body mass index (BMI = weight [in
kg]/height2 [in m2]) was calculated as a measure of obesity. The World
Health Organization reports the following categories for BMI: obese (≥30
kg/m2), overweight (25.0–29.9 kg/m2), normal (18.5–24.9 kg/m2), and
underweight (<18.5 kg/m2) (18). Blood pressures were recorded to the
nearest mm Hg and hypertension was defined according to the guidelines
provided by the National Institutes of Health (systolic blood pressure >140
mm Hg and/or diastolic blood pressure >90 mm Hg or under antihyper-
tensive therapy) (19).
Lipid Profile Evaluation
High density lipoproteins (HDL) were separated by adding polyeth-
ylene glycol to fresh samples in order to precipitate other lipoproteins (20).
Total cholesterol, HDL cholesterol, and triglycerides concentrations in
serum were estimated by using appropriate enzymatic kits (CHOD-PAP®,
HDL-C Plus®, and GPO-PAP®, respectively; Boehringer, Manheim, Ger-
many). LDL cholesterol concentration was estimated by the original
Friedewald formula (21). Based on cholesterol and/or triglycerides levels
in serum, subjects were divided into normolipidemics (with total choles-
terol and triglycerides levels below 200 mg/dL and 150 mg/dL, respec-
tively) and hyperlipidemics, who had one or both parameters above these
reference values (22). At the laboratory, personnel were unaware of the sta-
tus (patient, risk, or reference subject) of the specimens.
Determination of Enzyme Activities
Measurement of SOD activity in erythrocytes and GPx in whole blood
were carried out with commercial kits (Ransod SD 125 and Ransel RS 506,
respectively; Randox Laboratories, UK). For both enzyme activities, results
were expressed per gram of hemoglobin, which was also determined by
using a commercial kit (HG 980, Randox kit).
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Determination of Total Thiols, α-Tocopherol, 
and Ceruloplasmin
Total thiols in plasma were measured spectrophotometrically using the
Ellman’s reagent (23). Serum α-tocopherol was evaluated by a reverse-phase
high-performance liquid chromatography (HPLC) method, according to
Julianto et al. (24). Cp in serum was determined by rate nephelometry using
a commercial kit (CER Beckman-Array® System(s), Germany).
Determination of Total MDA and Protein Carbonyls
Malondialdehyde was measured in serum by liquid chromatogra-
phy–mass spectrometry (LC/MS) according to a method derived from an
initial ultraviolet (UV) version (25) with an electrospray ionization (ESI)
positive detection mode and an internal standard (dideuterated tetra
methoxypropane) for correction of MDA protein binding (26). The car-
bonyl contents in plasma were evaluated according to Levine et al. (27)
and expressed as nanomoles per milligram of protein, being the protein
content determined based on the method of Lowry et al. (28).
Elemental Analysis
Concentrations of Fe, Cu, Zn, and Se in plasma and blood cells were
determined by the PIXE (particle-induced X-ray emission) multielemental
technique. This technique also allowed one to evaluate the levels of K and
Ca. The methodology applied is described elsewhere (29). The analytical
procedure was checked using Gent second-generation freeze-dried human
serum reference material (30), which was analyzed together in each sam-
ple batch. Differences in the certified value were below 5% for Fe and Se
and below 10% for Cu, Zn, K, and Ca.
Apo E Genotyping
DNA extraction was achieved through the method of Miller et al. (31).
Apo E genotyping started with a polymerase chain reaction (PCR) to
amplify a 267-basepair fragment from the exon 4 of the apo E gene. The
amplification products were then submitted to digestion with the HhaI
restriction endonuclease, as described elsewhere (32). Each apo E allele
yields a distinct pattern after electrophoresis on polyacrylamide gel
(32,33). Samples were analyzed in a random fashion and the laboratory
technician carrying out the genotyping procedures was blinded for the
cholesterol levels of the samples concerned.
Statistical Analysis
Statistical analysis was performed using STATISTICA 5.0 and SPSS
10.0 softwares. Data were expressed as mean ± standard deviation. The
presence of outliers was verified by running box plots, and when the
Redox Balance in Atherosclerosis 61
Biological Trace Element Research Vol. 112, 2006
parameters did not fit a Normal distribution, a logarithmic transformation
was performed (34). The values were analyzed using the Student’s t-test
for independent samples, with a significance level of p < 0.05. Correlation
analyses using the Pearson’s coefficient were also applied for assessing lin-
ear relationships between the evaluated parameters. A forward stepwise
discriminant analysis, using blood pressure, BMI, lipids (total cholesterol,
HDL cholesterol, and triglycerides), SOD and GPx activities, nonenzy-
matic parameters (total thiols, α-tocopherol, Cp), oxidative damage
parameters (total MDA and protein carbonyls), and apo E polymorphism
as variables, were also applied to help in predicting the shared variability
relative to each clinical group (35).
Apo E allele frequencies were estimated using the gene-counting
method, and a χ2 goodness-of-fit test was applied to evaluate the genetic
Hardy–Weinberg equilibrium (36). Apo E categories were created as fol-
lows: E2 (ε2/ε3), E3 (ε3/ε3), and E4 (ε3/ε4 and ε4/ε4) to explore the
allelic effect and to increase statistical power (37). The differences in apo
E genotypes between the studied groups were observed using a χ2 asso-
ciation test.
RESULTS
Groups Description and Clinical Characterization
Table 1 presents clinical and biochemical characteristics of the study
groups. Genders were pooled because no major differences were found
between them (data not shown). Furthermore, the majority of females
were at the postmenopausal stage and this fact contributes to the similar
probability of both genders for the occurrence of atherosclerotic events.
Also, Pedersen et al. (38) have reported no evident differences between
females and males based on the prevalence and extent of atherosclerosis.
Body mass index classified the mean value for the reference group as
a marginally normal one (Table 1), with 69% normal and 31% overweight
persons. In turn, the risk group was composed of 32.5% normal, 50% over-
weight, and 17.5% obese subjects and the pathological group by 25% nor-
mal, 62.5% overweight, and 12.5% obese patients. Patients and risk
subjects had higher blood pressures, but no differences were observed
either for systolic or diastolic blood pressures between these two groups
(Table 1). Higher values were found for total and LDL cholesterol levels in
the serum of risk subjects and of patients relative to the reference group
(Table 1). Serum triglycerides levels were enhanced in risk subjects and
marginally higher in patients compared to levels of the reference ones
(Table 1). Total proteins in plasma were increased in patients compared to
risk subjects and the same trend was verified in relation to the reference
group, although not reaching statistical significance (p = 0.069) (Table 1).
As seen in Table 1, medicine intake was more pronounced in the patho-
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logical group, being the conjugation of the three therapies verified in 6% of
the patients.
Markers of Antioxidant Defenses and Oxidative Damage
The activities of SOD in erythrocytes and GPx in whole blood and the
plasma levels of total thiols kept unchanged across the three groups (Table
2). Serum α-tocopherol concentration was increased in atherosclerotic
patients (Table 2). Ceruloplasmin levels in serum were similar for the three
groups (Table 2). Figure 1 shows the variations of total MDA serum levels
and plasma protein carbonyl contents among the three groups. Total MDA
was similar between patients and references, but reached the highest values
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Table 1
Baseline Characteristics for Each Group
Note: Data are expressed as mean ± standard deviation, except when oth-
erwise indicated. Values in each row sharing the same superscript are signif-
icantly different (t-test, p < 0.05).
in risk subjects, this variation being statistically significant relative to the ref-
erence group (Fig. 1A). In turn, the level of protein carbonyls was the lowest
in the plasma of patients (Fig. 1B).
Elemental Analysis
Table 3 shows that the concentrations of K, either in plasma or in
blood cells, were higher in patients in relation to risk subjects and in blood
cells in relation to reference ones. Ca concentration in plasma was elevated
in the pathological group (Table 3). Fe, Cu, and Zn levels remained
unchanged across the three groups regardless of the biological compart-
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Table 2
Activities of SOD in Erythrocytes and GPx in Whole
Blood, Levels of Plasma Total Thiols, Serum α-Tocopherol,
and Cp for Each Group
Note: Data are expressed as mean ± standard deviation. Values in
each row sharing the same superscript are significantly different (t-
test, p < 0.05).
Fig. 1. Markers of oxidative damage for each group: (A) total MDA in serum;
(B) protein carbonyls in plasma. Bars sharing the same superscript are signifi-
cantly different (t-test, p < 0.05).
ment (Table 3). Risk subjects presented higher levels of Se in plasma rela-
tive to reference ones (Table 3).
Distribution of apo E Genotypes
The distribution of apo E genotypes in this study is in Hardy–Wein-
berg equilibrium (Table 4). The genotypes ε2/ε2 and ε2/ε4 were not found,
although all three alleles were represented in our samples (Table 4). The
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Table 3
Elemental Concentrations (mg/L) in Plasma 
and Blood Cell Fractions for Each Group
Note: Data are expressed as mean ± standard deviation. Values in each row sharing the same
superscript are significantly different (t-test, p < 0.05).
Table 4
Distribution of apo E Genotypes for Each Group
a χ2: Statistic between observed and expected values under Hardy–Wein-
berg equilibrium.
majority of subjects within each group were homozygous ε3/ε3 (Table 4).
However, an increase in the occurrence of the risk genotypes for atheroge-
nesis (ε3/ε4 and ε4/ε4) was observed from the reference group to patients,
and an inverse trend was verified for the common ε3/ε3 genotype (Table
4). This last observation is reinforced by the allelic frequencies. Moreover,
the proportion of the E3 genotypes category was proved to be different
between the risk group and the others (reference/risk: χ2 = 5.8, df = 1, p =
0.05; risk/pathological: χ2 = 14.3, df = 1, p = 0.05). The same observation
could be applied for the E4 genotypes category between the reference and
pathological groups (χ2 = 4.5, df = 1, p = 0.05).
Multivariate Analysis
The variations of the parameters based on atherosclerosis disease sta-
tus were assessed by discriminant analysis (Fig. 2). The first function (p =
0.000) to which the variables total cholesterol, systolic blood pressure,
diastolic blood pressure, total MDA, HDL cholesterol and triglycerides
were related to (discriminant loadings 0.562, 0.271, 0.255, 0.237, 0.184, and
0.180, respectively) explained 62% of the variations and separated the ref-
erence group from the others. The second discriminant function (p = 0.000)
was associated with α-tocopherol, protein carbonyls, total thiols, and apo
E polymorphism (discriminant loadings –0.545, 0.281, –0.254, and –0.167,
respectively) explained the remaining 38% of the variations and segre-
gated the pathological group from the risk group (Fig. 2).
DISCUSSION
Oxidative processes and inflammation are key components of athero-
sclerosis, from fatty streak formation to plaque rupture and thrombosis.
Recent clinical studies have identified potentially clinically useful markers
of oxidative stress and inflammation (17). In this study, we report on the
usefulness of the relationship between those parameters and the major risk
factors (including genetic markers) in humans from health to atheroscle-
rosis disease.
Variations in Antioxidant Defenses and Oxidative Markers
Both SOD and GPx activities, either of patients or of subjects from the
risk group, were not different from those of reference subjects. SOD is an
important antioxidant enzyme and, contrary to our findings, some studies
have reported decreased SOD activity in the erythrocytes of subjects suf-
fering from ischemia (39). It is believed that low SOD activity contributes
to higher levels of the superoxide radical, which can be implicated in the
pathogenesis of atherosclerosis (40). The protective effect of GPx in partic-
ular on lipoperoxidation is reinforced because this enzyme not only elimi-
nates hydrogen peroxide but also converts some lipid hydroperoxides to
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nontoxic alcohols, acting as a chain-breaking antioxidant (41). In studies
on atherosclerotic obliterans patients, a decline in the antioxidative barrier
of plasma because of reduced GPx activity has been reported (42) and
experimental evidence exists for a weak glutathione-related enzymatic
antioxidant shield in human atherosclerotic plaques, resulting from the
absence of GPx activity in atherosclerotic tissue (43). In contrast, Wein-
brenner et al. (44) suggested that oxidative stress might occur in patients
with stable coronary heart disease, based on enhance activities of SOD in
erythrocytes and GPx in whole blood, even in patients clinically stable and
under medical treatment, like the patients of our study. Thus, contradic-
tory findings exist for these enzyme activities in the atherosclerotic condi-
tion. The comparison of data from different studies must be made
carefully because, in general, the experimental conditions are not identical,
including some of the major risk factors associated with this pathology,
such as cigaret smoking (Lopes et al., unpublished data) and medicine
intake. In fact, recent data suggested that statins, in addition to their lipid
lowering activity, can reduce the production of reactive oxygen species
and increase the resistance of LDL to oxidation (45).
Thiols are compounds containing sulfhydryl residues, and in biologi-
cal systems, they are involved in protein synthesis and structure and play
an important role in redox-sensitive signal transduction, immune regula-
tion, and coordinating the antioxidant defense network (46). Disturbances
in tissue thiol homeostasis have been linked to several human health dis-
orders (46). In our study, the levels of total thiols in plasma were similar in
patients and in reference subjects. However, patients with coronary artery
Redox Balance in Atherosclerosis 67
Biological Trace Element Research Vol. 112, 2006
Fig. 2. Scatterplot of the canonical discriminant functions, indicating the
centroids (cross) for each group (R, square: reference group; RK, diamond: risk
group; P, circle: pathological group) (for details see the Materials and Methods
section).
disease have been described as having decreased concentrations of plasma
protein thiols (47).
Vitamin E is the major lipid-phase antioxidant protecting against
oxidative lipid damage (5). It is thought to be effective in preventing ath-
erosclerosis (12), because a local or generalized diminution of α-tocopherol
concentration caused by dietary or oxidative factors can stimulate cell
growth and lead to atherosclerosis progress (48). However, supplements of
dietary vitamin E in clinical trials have not prevented consistently cardiac
attacks in humans with established coronary heart disease, and vitamin E
might become an oxidant agent (2,49,50). Such contradictory results have
questioned the role of vitamin E as a protective agent in human athero-
sclerosis (51). In the present study, the highest levels of serum α-tocopherol
were found in atherosclerotic patients, but this finding disagrees with oth-
ers (as discussed later in this subsection) and could be justified by a
healthy diet recommended by physicians. In turn, the serum level of α-
tocopherol for the risk group was similar to that of the reference one,
which is not in accordance with data reported elsewhere on decreased
serum α-tocopherol concentration in subjects with various coronary risk
factors including male gender, higher age, smoking habits, altered serum
lipid profile, and obesity (52). It is not clear whether the vitamin E decrease
is a result of the ongoing atherosclerotic process by itself or contributes to
its further aggravation (12). In several clinical trials, patients with coronary
heart and artery diseases and after stroke presented unchanged α-toco-
pherol status (12,47,53).
In the present study, a positive correlation between total MDA and pro-
tein carbonyls (r = 0.33; p < 0.05) was found, supporting the view that dif-
ferent biomolecules can be damaged by oxidants. No differences were found
in MDA concentration between healthy and atherosclerotic subjects, which
agrees with data published by Weinbrenner et al. (44) for males with coro-
nary heart disease. However, previous studies have shown that subjects
with ischemic heart disease, unstable angina, stable angina, or myocardial
infarction have higher levels of MDA (11,54). One possible explanation for
our results is the presence of both genders in the pathological group because
estrogens could act as a confounding factor on the circulating levels of
MDA, as stated by Fabbi et al. (4). Also, the apparent absence of lipid per-
oxidation in these patients might be a result of the tight and successful reg-
ulation of lipids contents by statins, mainly total cholesterol, whose mean
value, although increased, did not reach a hazardous level (above 250
mg/dL) (4,45). Notwithstanding, higher values of total MDA were found in
risk subjects with hyperlipidemic profile compared to reference ones, which
could be eventually explained by the absence of statins intake. In addition,
this result supports our own previous report in which the hyperlipidemia
condition (without atherosclerotic events) led to higher lipoperoxidation
levels, quantified through TBARS method (Lopes et al., unpublished data).
The evaluation of the carbonyl groups in plasma proteins is a
respected marker of free-radical reaction intensity (27,55) in aging and in
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various diseases (56–58). In our study, lower levels of protein carbonyls
were found in the pathological group, which had a slightly higher protein
concentration compared to the reference group. This result is not in accor-
dance with previous findings that defend the accumulation of protein car-
bonyls in vascular lesions as a common phenomenon in most, if not all,
types of vascular damage (56). However, in our study, the higher plasma
protein level in the pathological group could lead to a carbonyl/protein
ratio lower than that observed in the other groups. In turn, higher car-
bonyls and lower protein concentrations were found in the plasma of risk
subjects, suggesting, for this group, signs of free-radical attack. These
results are in fact corroborated by the negative correlation observed
between total proteins and protein carbonyls (r = –0.74; p < 0.05).
Variations in Elemental Status
In this study, potassium and calcium were slightly elevated in patients,
suggesting alterations in elemental homeostasis probably the result of
changes in cellular ion transport related to the atherosclerotic process. Thus,
the variations found for these elements might reflect an electrolytic imbal-
ance. On the other hand, in vitro studies have reported an intracellular cal-
cium rise due to oxidized LDL (59), which promotes the activation of T-cells
(60) and could establish an interesting relationship among the oxidative
stress, the inflammatory process, and the electrolytic balance.
Iron blood levels remained unchanged, but total proteins correlated pos-
itively with this element in plasma (r = 0.33; p < 0.05). This association could
be justified by the existence of several iron-containing proteins, such as fer-
ritin, transferrin, haemoglobin, myoglobin, or the hemin moiety (61). Recent
studies have demonstrated that iron deposition is prominent in human ath-
erosclerotic lesions, and animal experiments have further revealed that the
severity of atherosclerosis can be markedly influenced by iron overload or
deficiency (62). In fact, iron has been inconsistently associated with cardio-
vascular disease in spite of the plausible hypothesis as to how transition
metal might accelerate the progression of atherosclerosis (63). Free iron is
deleterious to cells because it catalyzes the generation of hydroxyl radicals
from superoxide and hydrogen peroxide via the Fenton reaction (62).
In this study, unchanged blood levels of copper and iron in athero-
sclerotic patients agrees with the maintenance of serum Cp concentration.
Cp is a α2-globulin acting as a multicopper oxidase playing a role in iron
metabolism, through its ferroxidase activity (42,61,64). The physiologic
importance of this protein might include antioxidant activity by promot-
ing iron mobilization or scavenging free radicals and, thus, preventing
metal-catalyzed free-radical tissue damage. On the other hand, the puta-
tive role of Cp as a risk factor for atherosclerosis and cardiovascular dis-
ease has been attributed to its pro-oxidant activity to modify LDL
(61,64,65). Previous studies on atherosclerosis obliterans showed that Cp
activity and copper concentration in serum were increased and correlated
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in this pathology (42,66). This correlation supports in part the positive
associations found in our study between Cp and copper (in plasma and
blood cells: r = 0.73, r = 0.45; p < 0.05, respectively), although the absolute
Cp concentration has been measured instead of its activity.
Zinc levels, either in plasma or in blood cells, were similar for all the
studied groups. In contrast, Isra and Majewski (66) have found zinc lev-
els greatly enhanced in the serum of atherosclerosis obliterans patients.
The meaning of this finding is not clear, as several studies propose zinc
to be antiatherogenic, through either its inhibition of LDL oxidation or its
role in inhibition of the oxidative-stress-responsive factors involved in
destruction of vascular endothelial cell integrity (3,67). Furthermore,
severe and moderate zinc deficiency has been reported to cause oxidative
damage to proteins, lipids, and DNA in rat testes, which might be the
result of iron accumulation or a reduction in zinc-dependent antioxidant
processes (68).
Concentrations of selenium in plasma can provide useful indicators of
human selenium intake and status (69). In this study, risk subjects presented
higher levels of selenium in plasma than the reference ones, which might be
related to the presence of approximately 80% of hyperlipidemic subjects in
the risk group (70). This association could in part be the result of the bind-
ing of selenium to lipoproteins, mainly LDLs, which are recognized as hav-
ing significant amounts of selenium (71). Moreover, epidemiological studies
are known to be controversial with respect to the association of this element
and the occurrence of cardiovascular diseases (72), although a protective
role has been attributed to selenium in reducing the risk for heart diseases
and cancer (73,74).
Variations in apo E Polymorphism
In recent years, several polymorphisms playing a role in the develop-
ment and progression of atherosclerosis have been identified in relation to
blood coagulation, endothelial function, and lipid metabolism (75), as is
the case of apo E. The serum cholesterol concentration is in part deter-
mined by the common apo E polymorphism and the ε4 allele appears to be
associated with elevated serum cholesterol concentration (6,76–78) and to
contribute to an increased risk for coronary artery disease and atheroscle-
rosis (37,79,80). In this study, the high-risk genotypes for atherogenesis
(ε3/ε4 and ε4/ε4) were found in a higher percentage in patients, similarly
to results of Stengard et al. (81,82) and to those of Pirim et al. (83). These
hazardous genotypes were also found in risk subjects. These findings
agree with the above-mentioned association between the ε4 allele and the
incidence of atherosclerosis. Moreover, intervention trials in humans as
well as experimentation in animal models have demonstrated a connec-
tion between apo E and atherosclerosis. It is the case of experiments with
apo E-null mutant mice that are hypercholesteremic animals, which rap-
idly developed atherosclerotic lesions, either when kept on an atherogenic
diet or on a normal chow (84).
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FINAL REMARKS
The maintenance of some antioxidant defenses in atherosclerotic
subjects observed in this study could be consequence of medical treat-
ment. Nevertheless, a multivariate model applied to all the subjects
clearly discriminated the three groups at study (i.e., the healthy group
from the group in a steady state of risk disease and from the atheroscle-
rotic one). These findings point out the need for further coordinated
studies using complementary markers, both at biochemistry and genet-
ics levels, in order to enlighten our knowledge about atherosclerosis
molecular mechanisms.
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